Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03533283
Other study ID # NP39488
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 8, 2018
Est. completion date September 30, 2026

Study information

Verified date April 2024
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients. This study includes an additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin's lymphoma to image CD8+T-cells at baseline and after treatment with glofitamab, including pre-treatment with obinutuzumab.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 280
Est. completion date September 30, 2026
Est. primary completion date September 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Main Inclusion Criteria - Histologically-confirmed hematologic malignancy that is expected to express CD20 (Relapsed after or refractory to respond to at least one prior treatment regimen; no available treatment options that are expected to prolong survival or patients refusing chemotherapy or autologous stem cell transplant (SCT). Note: The expansion part is restricted to relapsed/refractory follicular lymphoma (r/r FL) and relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL)) - At least one measurable target lesion - Fresh pre-treatment biopsy, but if this cannot be taken, a previous archived biopsy from metastatic lesion can be taken as replacement if it is not older than 6 months and not confounded by major events (progression, treatment) - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Adequate organ function (liver, hematological, renal) - Negative test results for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) Inclusion Criteria Specific to Imaging Substudy - At least two measurable target lesions - Able to provide two fresh tumor biopsies (baseline and on-treatment) Main Exclusion Criteria - Participants with Chronic Lymphocytic Leukemia (CLL), acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma, Richter's transformation, CD20-positive ALL, Burkitt lymphoma, or lymphoplasmacytic lymphoma - Current > Grade 1 peripheral neuropathy (only for participants being treated in the polatuzumab vedotin arm) - Patients with known active infection, or reactivation of a latent infection within 4 weeks prior to Obinutuzumab (Gpt) infusion - Patient with history of confirmed progressive multifocal leukoencephalopathy (PML) - History of leptomeningeal disease - Current or past history of central nervous system (CNS) lymphoma - Current or past history of CNS disease - Major surgery or significant traumatic injury </=28 days prior to Gpt infusion - Significant cardiovascular disease or significant pulmonary disease - Active or history of autoimmune disease or immune deficiency (with exceptions, e.g. hypothyroidism and Diabetes mellitus Type 1) - History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan - Treatment with any other standard anti-cancer radiotherapy / chemotherapy including investigational therapy within 4 weeks prior to Gpt infusion - Prior solid organ transplantation - Prior allogenic stem cell transplant (SCT) - Autologous SCT within 100 days prior to Gpt infusion - Documented refractoriness to an obinutuzumab-monotherapy regimen - Prior treatment with anti-cancer/lymphoma therapies and systemic immunotherapeutic/immunostimulating agents within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to Gpt infusion - Any history of immune related >/= Grade 3 adverse events (AE) with the exception of endocrinopathy managed with replacement therapy - Ongoing corticosteroid use >25 milligrams/day of prednisone or equivalent within 4 weeks prior to and during study treatment - Treatment with systemic immunosuppressive medication - Administration of a live, attenuated vaccine within 4 weeks prior to Gpt infusion or anticipation that such a live attenuated vaccine will be required during the study or within 5 months after last dose of study treatment Exclusion Criteria Specific to Imaging Substudy - Circulating lymphoma cells, defined by out of range (high) absolute lymphocyte count and/or the presence of abnormal/malignant cells in the peripheral blood differential signifying circulating lymphoma cell - Participants who have had splenectomy or functional asplenia that could compromise protocol objectives

Study Design


Intervention

Drug:
Glofitamab
Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
Atezolizumab
Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
Obinutuzumab
Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
Tocilizumab
Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
Polatuzumab Vedotin
Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
89Zr-Df-IAB22M2C
Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.

Locations

Country Name City State
Belgium UZ Gent Gent
Denmark Aarhus Universitetshospital Skejby; Blodsygdomme Aarhus N
Denmark Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT København Ø
Denmark Odense Universitetshospital; Hæmatologisk Afdeling Odense C
Israel Hadassah Ein Karem Hospital; Haematology Jerusalem
Israel Rabin Medical Center-Beilinson Campus;Hematology-Oncology Petach Tikva
Israel Chaim Sheba Medical Center; Department of Hematology Ramat-Gan
Italy ASST PAPA GIOVANNI XXIII; Ematologia Bergamo Lombardia
Italy Policlinico S.Orsola-Malpighi;Istituto di Ematologia "Seragnoli" Bologna Emilia-Romagna
Italy Fond. IRCCS Istituto Nazionale Tumori; S. C. Ematologia Milano Lombardia
Italy Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica Napoli Campania
Spain Hospital Duran i Reynals; Servicio de Hematologia Barcelona
Spain Hospital Universitari Vall d'Hebron; Servicio de Hematologia Barcelona
Spain START Madrid-FJD, Hospital Fundacion Jimenez Diaz Madrid
Spain Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia Malaga
Spain Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia Valencia
United Kingdom The HOPE Clinical Trials Unit Leicester
United Kingdom University College London Hospitals NHS Foundation Trust; NIHR UCLH Clinical Research Facility London
United Kingdom The Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne
United States Novant Health Cancer Institute Charlotte North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Belgium,  Denmark,  Israel,  Italy,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose Limiting Toxicities (DLTs) Atezolizumab Arm: During DLT period of 21 days (or up to 42 days in the case of cycle delay), starting on Day 1, Cycle 2; Polatuzumab Vedotin Arm: During 5-week DLT period starting Cycle 1, Day 8
Primary Change in Maximum Standardized Update Value (SUVmax) Based on 89Zr-PET/CT Scans From baseline to Day 13
Primary Change in Peak SUV (SUVpeak) Based on 89Zr-PET/CT Scans From baseline to Day 13
Primary Change in Mean SUV (SUVmean) Based on 89Zr-PET/CT Scans From baseline to Day 13
Primary Change in CD8 Tumor Volume Based on 89Zr-PET/CT From baseline to Day 13
Secondary Percentage of Participants with Adverse Events (AEs) Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Anti-Drug Antibody (ADA) Formation Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Complete Response (CR) Rate, as Assessed by Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) Scan Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Objective Response Rate (ORR) Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Disease Control Rate (DCR) Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Duration of Response (DOR) Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Duration of Complete Response Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Time to First Complete Response (TFCR) Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Time to First Overall Response (TFOR) Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Progression-Free Survival (PFS) Baseline until end of treatment (13 to 14 months), then every 3 months until end of study visit (to occur within 4 weeks of disease progression)
Secondary Overall Survival (OS) Baseline through end of survival follow-up phase (survival follow-up is every 3 months until death, lost to follow-up, withdrawal of consent, or study termination)
Secondary Elimination Half-Life (T1/2) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)
Secondary Area Under the Concentration-Time Curve (AUC) for Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)
Secondary Time to Maximum Observed Serum Concentration (Tmax) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)
Secondary Maximum Observed Serum Concentration (Cmax) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)
Secondary Minimum Serum Concentration (Cmin) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)
Secondary Clearance (CL) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)
Secondary Volume of Distribution at Steady-State (Vss) of Glofitamab Administered in Combination with Atezolizumab or Polatuzumab Vedotin At pre-defined intervals through the end of study (EoS) visit (to occur within 4 weeks of disease progression)
Secondary CD8-Positive T Cell Proliferation At pre-defined intervals during the study treatment period (up to 17 cycles; Cycle = 21 days)
Secondary CD20-Positive B-Cell Reduction At pre-defined intervals during the study treatment period (up to 17 cycles; Cycle = 21 days)
Secondary SUVmax of 89Zr-Df-IAB22M2C From baseline to Day 13
Secondary SUVpeak of 89Zr-Df-IAB22M2C From baseline to Day 13
Secondary SUVmean of 89Zr-Df-IAB22M2C From baseline to Day 13
Secondary Tumor Volume Based on 89Zr-Df-IAB22M2C PET-uptake From baseline to Day 13
Secondary Quantitation of CD8+ Cells on Biopsy Samples From baseline to Day 13
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04240704 - Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL Phase 1
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Recruiting NCT00807196 - Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00764829 - Blood Samples to Evaluate Biomarkers of Donor Chimerism N/A
Completed NCT00726934 - The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients N/A
Completed NCT01517581 - Brown Fat Activity and White Fat Accumulation N/A
Completed NCT00193505 - Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma Phase 2
Terminated NCT01744912 - Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Phase 1
Terminated NCT01500161 - Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Phase 2
Active, not recruiting NCT00001379 - Treatment and Natural History Study of Lymphomatoid Granulomatosis Phase 2
Completed NCT00574730 - CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma N/A
Completed NCT00901225 - Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant Phase 2
Terminated NCT01598025 - Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor N/A
Terminated NCT01326728 - Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
Completed NCT01290549 - A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma Phase 1
Completed NCT00807677 - A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies Phase 1
Completed NCT00837200 - Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies Phase 2
Terminated NCT00054834 - Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma Phase 1
Terminated NCT00003500 - Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma Phase 2
Active, not recruiting NCT02099266 - Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment N/A